کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
8679180 | 1579115 | 2017 | 22 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
کاردیولوژی و پزشکی قلب و عروق
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
Programmed cell death ligand (PD-L1) has been studied as a predictive immunotherapy biomarker. We investigated PD-L1 expression in the whole tumor and in tumor-infiltrating macrophages (TIMs) as a prognostic biomarker in surgically resected pathologic stage I non-small cell lung cancer. Pathologic specimen from 113 patients with stage I lung cancer (pT1-2a, N0, M0, tumor size 1-5âcm, 79 adenocarcinoma, 34 squamous cell carcinoma) were analyzed for PD-L1 expression in the tumor and in the TIMs using immunohistochemistry and image analysis. Statistics included recursive partitioning, univariable, multivariable, and Kaplan-Meier analyses. Patients whose tumors expressed <4.7% PD-L1 (Nâ=â87) experienced significantly better overall survival (OS) (Pâ=â0.001) than patients with PD-L1 >4.7% (Nâ=â26). Patients with PD-L1 expression in macrophagesâ<6.3% (Nâ=â24) also experienced significantly better (Pâ=â0.005) OS than patients with >6.3% (Nâ=â89). The best outcomes were observed in patients with low PD-L1 expression in both tumor and macrophages with 5-year OS of 94% (Nâ=â17). Contrarily, patients with high PD-L1 expression in both tumor and macrophages experienced 5-year OS of 20% (Nâ=â19). Low PD-L1 expression in the tumor and in the TIMs was independently associated with survival in multivariable analysis (Pâ=â0.000 and Pâ=â0.030, respectively). Lower PD-L1 % expression in the tumor and in the TIMs seems to be associated with significantly better OS in surgically resected stage I lung cancer. Additional studies are needed to validate PD-L1 as a prognostic biomarker in lung cancer and to study the mechanisms of intratumoral immune response.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Seminars in Thoracic and Cardiovascular Surgery - Volume 29, Issue 3, Autumn 2017, Pages 408-415
Journal: Seminars in Thoracic and Cardiovascular Surgery - Volume 29, Issue 3, Autumn 2017, Pages 408-415
نویسندگان
Boris MD, Edwin Parra PhD, Jaime Rodriguez MD, Carmen MD, Arlene M. PhD, Ara MD, Annikka MD, Neda MD, Cesar MD, Stephen MD, Ignacio MD,